588 related articles for article (PubMed ID: 26457018)
1. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
Kanda M; Sugimoto H; Kodera Y
World J Gastroenterol; 2015 Oct; 21(37):10584-97. PubMed ID: 26457018
[TBL] [Abstract][Full Text] [Related]
2. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N
Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068
[TBL] [Abstract][Full Text] [Related]
4. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide identification of differential methylation between primary and recurrent hepatocellular carcinomas.
Cui C; Lu Z; Yang L; Gao Y; Liu W; Gu L; Yang C; Wilson J; Zhang Z; Xing B; Deng D; Sun ZS
Mol Carcinog; 2016 Jul; 55(7):1163-74. PubMed ID: 26138747
[TBL] [Abstract][Full Text] [Related]
6. Detection of epigenetic aberrations in the development of hepatocellular carcinoma.
Zhang Y
Methods Mol Biol; 2015; 1238():709-31. PubMed ID: 25421688
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation in hepatocellular carcinoma.
Tischoff I; Tannapfe A
World J Gastroenterol; 2008 Mar; 14(11):1741-8. PubMed ID: 18350605
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.
Khan FS; Ali I; Afridi UK; Ishtiaq M; Mehmood R
Hepatol Int; 2017 Jan; 11(1):45-53. PubMed ID: 27271356
[TBL] [Abstract][Full Text] [Related]
10. The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Chong DQ; Tan IB; Choo SP; Toh HC
Contemp Clin Trials; 2013 Nov; 36(2):605-15. PubMed ID: 23591326
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic molecular markers in hepatocellular carcinoma.
Mínguez B; Lachenmayer A
Dis Markers; 2011; 31(3):181-90. PubMed ID: 22045404
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
Nishida N; Kitano M; Sakurai T; Kudo M
Dig Dis; 2015 Oct; 33(6):771-9. PubMed ID: 26488287
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
14. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
[TBL] [Abstract][Full Text] [Related]
15. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.
Su H; Zhao J; Xiong Y; Xu T; Zhou F; Yuan Y; Zhang Y; Zhuang SM
Mutat Res; 2008 May; 641(1-2):27-35. PubMed ID: 18358501
[TBL] [Abstract][Full Text] [Related]
16. Met as a therapeutic target in HCC: facts and hopes.
Giordano S; Columbano A
J Hepatol; 2014 Feb; 60(2):442-52. PubMed ID: 24045150
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of the epigenetic regulator SETDB1 in liver carcinogenesis-more than one way to skin a cat.
Longerich T
Chin Clin Oncol; 2016 Dec; 5(6):72. PubMed ID: 27164857
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
19. Methylation profiling of tumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in northern India.
Kiran M; Chawla YK; Kaur J
Cancer Genet Cytogenet; 2009 Dec; 195(2):112-9. PubMed ID: 19963110
[TBL] [Abstract][Full Text] [Related]
20. DNA Methylation and Micro-RNAs: The Most Recent and Relevant Biomarkers in the Early Diagnosis of Hepatocellular Carcinoma.
Cozma A; Fodor A; Vulturar R; Sitar-Tăut AV; Orăşan OH; Mureşan F; Login C; Suharoschi R
Medicina (Kaunas); 2019 Sep; 55(9):. PubMed ID: 31546948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
